SINTX Technologies, Inc. (NASDAQ:SINT) ("SINTX" or the "Company"), an advanced biomaterials company focused on developing silicon nitride technologies for medical applications, today announced that it has entered into securities purchase agreements with institutional and accredited investors pursuant to which the Company agreed to issue and sell an aggregate of 1,882,845 shares of common stock in a private placement priced at-the-market under Nasdaq rules.

In addition, the Company issued to the investors (i) Class A Common Stock Purchase Warrants to purchase up to an aggregate of 1,882,845 shares of common stock and (ii) Class B Common Stock Purchase Warrants to purchase up to an aggregate of 1,882,845 shares of common stock. The warrants are exercisable immediately at an exercise price of $2.14 per share. The Class A Warrants will expire five years from the date of issuance and the Class B Warrants will expire two years from the date of issuance. The combined effective offering price for each share of common stock and accompanying warrants to be issued is $2.39. The offering is expected to close on or about June 3, 2026, subject to satisfaction of customary closing conditions.

The aggregate gross proceeds to the Company from the private placement were $4.5 million before deducting fees and other offering expenses. Together with a previously completed $500,000 purchase of the Company's common stock through its at-the-market offering program, the Company has raised approximately $5.0 million of equity capital in recent weeks. The Company intends to use the net proceeds from the offering for general corporate purposes, including working capital, commercialization activities, business development initiatives and other strategic opportunities.